Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates.
about
Analysis of the genome to personalize therapy for melanomaReceptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cellsMelanoma: oncogenic drivers and the immune systemMelanoma: new insights and new therapiesPathways and therapeutic targets in melanomaCIViC databaseTargeting TBK1 inhibits migration and resistance to MEK inhibitors in mutant NRAS melanoma.Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trialsA melanoma molecular disease modelPhase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma.Beyond histology: translating tumor genotypes into clinically effective targeted therapies.Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignanciesClinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KITFuture of personalized medicine in oncology: a systems biology approach.It's about time: lessons for solid tumors from chronic myelogenous leukemia therapyNew strategies in melanoma: molecular testing in advanced disease.Recurrent inflammatory myofibroblastic tumors harboring PIK3CA and KIT mutations.Novel dual Src/Abl inhibitors for hematologic and solid malignancies.Therapy for metastatic melanoma: the past, present, and future.Targeted therapy for melanoma: a primer.Driver mutations in melanoma: lessons learned from bench-to-bedside studiesA phase 2 trial of dasatinib in advanced melanoma.Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanomaPhase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanomaOncogenic mutations in melanomas and benign melanocytic nevi of the female genital tract.Combined inhibition of MEK and mTOR has a synergic effect on angiosarcoma tumorgraftsNovel biomarkers and therapeutic targets for optimizing the therapeutic management of melanomasThe current state of targeted therapy in melanoma: this time it's personalTargeting drivers of melanoma with synthetic small molecules and phytochemicals.Antitumor T-cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40.Drug targets and predictive biomarkers in the management of metastatic melanoma.NeuroD1 regulation of migration accompanies the differential sensitivity of neuroendocrine carcinomas to TrkB inhibitionPhase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT InhibitionThin and thick primary cutaneous melanomas reveal distinct patterns of somatic copy number alterations.SRC family kinase inhibition as a novel strategy to augment melphalan-based regional chemotherapy of advanced extremity melanoma.Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors.KIT as a therapeutic target in metastatic melanoma.BRAF and beyond: Tailoring strategies for the individual melanoma patientTargeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics.Immune-related biomarkers for diagnosis/prognosis and therapy monitoring of cutaneous melanoma.
P2860
Q24601008-55484C03-255C-4F2B-BC4E-00A092BC68F2Q26740953-4A31694F-F5B5-4B17-B80F-ED6C5A1250D3Q26775598-1F6D9053-A61A-42D2-B398-AAA10EA087A2Q26853127-9ACB283B-5CCC-42E9-A9E4-45CB214E8542Q26865736-638DE692-17B1-4EE2-BFCF-7E1DECB815D8Q27612411-1B53EF08-03E2-4212-8895-8331AABEB578Q27853026-082B6C1E-6C49-49EE-A6B9-2A849CAF0B4DQ28730438-CC57015F-5E1F-4C4D-91AF-BDC54B455169Q28741507-83801673-F848-47EE-8BB9-06F2CBACE56FQ33399049-E34F3F88-7AC6-4564-AE7B-20E9E0217E97Q33560928-C7C817F3-675E-45DC-8E2E-D9B109E9CC7FQ33572971-287482AD-1320-417E-A0DF-2FC9621BF2CFQ33794917-F5F3AD0C-2814-429F-8367-428CA634E9FAQ33898189-4022CAC0-AE64-4DAB-8AB2-1FBD69BA41B2Q33936071-34C9C472-D2C3-4F20-A3B8-9CAB20C3542EQ33943660-0EF901C5-AD38-4E0A-9EB6-1096B3B48466Q34028920-9B443346-A50F-43D2-B0CD-45B94D7E7FBEQ34121339-1A7BF6BF-5F26-4A9A-A684-C36A0D65B67CQ34183225-460DF2BB-5928-419B-8E0B-9044D9ED4B18Q34540273-8AD7BE0F-2672-4385-B49B-5A548CB5205BQ34639532-A573CFFE-DC0C-4328-966E-3A8BFC31330DQ35048145-D01CA969-DF81-4A5F-A7DB-B456CF13CD12Q35093281-B84EC312-0557-45A2-A0F4-7789B97BEF8AQ35653813-211E2BB4-9451-45A5-971C-12EE9E9B3DF1Q35670595-331AE7DB-A3A8-442D-BA12-CC66AD990206Q35798540-4302FA3E-1AB1-4D26-8477-3247B11DA33FQ35845352-5611DE38-4B49-42E0-990C-EDDD9674C0B9Q35878248-953F9C39-607E-414C-97A5-84B590555E47Q36141097-DD48C645-A1FD-463C-B362-ABFE3B325179Q36440066-9FC7286E-FFF4-44F9-8587-B657A95DBDA3Q36441552-243F22FD-8138-4B24-BE2A-B2A8E2C515D0Q37137259-09FF4061-67B5-4006-92CB-511C7E3036B0Q37237619-32119F2A-6B1D-4FCC-B3D7-FD63FDCB2300Q37327493-6258486B-0759-473D-8A5B-20F7E7C9B197Q37509699-9AF039AE-4E7E-43A8-B42B-9B71E0C24F6AQ37613072-A8F85E2F-D0B3-4547-B2B9-5EDBF09A6327Q37701887-6C1D456D-5968-46C3-9E3D-81C0D646B53CQ37702515-19D8207F-80AE-43CA-86D5-C460CBC47ECEQ37748089-B39EB9AC-F1C0-4AD1-AFD8-1199B6D90EBBQ37801939-0837F8BB-7797-4607-BF10-7F523654034C
P2860
Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates.
description
2009 nî lūn-bûn
@nan
2009 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Activity of dasatinib against ...... ular, and clinical correlates.
@ast
Activity of dasatinib against ...... ular, and clinical correlates.
@en
Activity of dasatinib against ...... ular, and clinical correlates.
@nl
type
label
Activity of dasatinib against ...... ular, and clinical correlates.
@ast
Activity of dasatinib against ...... ular, and clinical correlates.
@en
Activity of dasatinib against ...... ular, and clinical correlates.
@nl
altLabel
Activity of dasatinib against ...... lular, and clinical correlates
@en
prefLabel
Activity of dasatinib against ...... ular, and clinical correlates.
@ast
Activity of dasatinib against ...... ular, and clinical correlates.
@en
Activity of dasatinib against ...... ular, and clinical correlates.
@nl
P2093
P2860
P50
P3181
P1476
Activity of dasatinib against ...... ular, and clinical correlates.
@en
P2093
Doina Ivan
Donald A Podoloff
Gordon B Mills
Jonathan C Trent
Kevin B Kim
Michael A Davies
Nicholas Papadopoulos
Patrick Hwu
Scott E Woodman
P2860
P304
P3181
P356
10.1158/1535-7163.MCT-09-0459
P577
2009-08-01T00:00:00Z